<DOC>
	<DOCNO>NCT00370084</DOCNO>
	<brief_summary>Itopride new compound already market Japan country Eastern Europe name Ganaton . It use treat symptom associate gastroparesis . Due inadequate gastric emptying , patient often symptoms bloat , nausea vomit follow ingestion meal . The goal study evaluate effect Itopride gastric motor function glycemia patient diabetes .</brief_summary>
	<brief_title>Itopride Hydrochloride Diabetes : Effects Gastric Emptying Glycemia</brief_title>
	<detailed_description>This mechanistic study evaluate cross-over design effect Itopride hydrochloride . The primary objective study evaluate acute effect itopride hydrochloride ( 200 mg three time daily ) gastric empty solid liquid meal component patient type 1 type 2 diabetes mellitus . Secondary objective evaluate effect itopride hydrochloride glycaemic response meal , `` meal-related '' upper gastrointestinal symptom intragastric meal distribution .</detailed_description>
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>Type1 Type2 diabetic patient 18 65 year old Glycated haemoglobin level ( HbA1c ) 9 % Body mass index ( BMI ) 18 35 kg/m2 Use medication potentially influence upper gastrointestinal motility appetite within one week study ( e.g . prokinetic drug , macrolide antibiotic ) Exposure radiation research purpose previous 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>